The Future of Cholesterol Management: Application of PCSK9 Inhibitors in Practice 2018- Webcast

Webcast Session

This course was a live CME-certified Ancillary Symposium presented at Endocrine Society Annual Meeting (ENDO) 2018, held in Chicago, IL.This educational activity is supported by an independent medical educational grant from Amgen. 


Target Audience

This activity is intended for endocrinologists and endocrine fellows, primary care and internal medicine physicians, cardiologists, physician's assistants, nurse practitioners, and other healthcare professionals caring for patients with lipid disorders including familial hypercholesterolemia.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Discuss the biology and genetic underpinnings of dyslipidemia as it relates to PCSK9 and the LDL receptor
  • Assess the value of newer therapies to treat patients with familial hypercholesterolemia and apply treatment
  • Evaluate strategies to optimize commonly used lipid-lowering therapies in patients with familial hypercholesterolemia

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Lipid Disorders and Fatty Liver Diseases
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.00 ABIM MOC
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
Course expires: 
Program Chair
Robert H. Eckel, MD
Professor of Medicine
University of Colorado Anschutz Medical Campus
Aurora, CO
Anne Carol Goldberg, MD, FACP
Professor of Medicine
Washington University School of Medicine
Saint Louis, MO
Henry N. Ginsberg, MD
Irving Professor of Medicine
Columbia University
New York, NY


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships during the content development process for this activity: 

Robert E. Eckel, MD

The faculty reported the following relevant financial relationship(s) during the content development process for this activity

Anne Carol Goldberg, MD, FACP: Advisory Board Member: Esperion, Sanofi, Regeneron. Grant Recipient: Amarin, Amgen, IONIS/Akcea, Pfizer, Regeneron, Sanofi, The Medicines Company. Editorial Work: Merck. Exam Committee: American Board of Internal Medicine

Henry N. Ginsberg, MD: Advisory Board Member (Self): Amgen Inc, Merck, Sanofi, Regeneron Pharmaceuticals. Advisory Board Member (Spouse): Kowa. Grant Recipient (Self): Amgen Inc, Merck, Sanofi, Sandoz. Research Investigator (Self): Merck, Regeneron Pharmaceuticals.

The following SPC member who reviewed content for this activity reported relevant financial relationships: 
Jonathan Purnell, MD: Advisor, Novo Nordisk
The following SPC Committee members reported financial relationships:
Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexcom, Novo Nordisk, Trividia Health
Giuseppe Barbesino, MD: Spouse, employee of Genzyme
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Natalie Cusano, MD: Research Support, Shire; Speaker, Shire
Joan Han, MD: Research Support, Rhythm Pharmaceutical
Steven T. Harris, MD: Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Merck, Radius Health; Speaker, Amgen, Eli Lilly & Company, Radius Health, Shire
Alan Kelly, MD: Speaker, Eli Lilly
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca/Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The following SPC members reported no relevant financial relationships:
Amy Rothberg, MD; Susmeeta Sharma, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
Click "Start" to complete meeting evaluation, claim CME, and print a certificate of attendance or certificate of participation.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™ and 2.0 ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions about content or obtaining CME credit, please contact the Endocrine Society at

Review your Diplomate ABIM ID Number(s)

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers (must be logged in to view):

    Your ABIM Number: [current-user:profile-profile:field-number-abim]*

    *If your ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.

  2. Update Profile

Available Credit

  • 2.00 ABIM MOC
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation